



TEW

1644

PATENT
ATTORNEY DOCKET NO. 50304/059001

Certificate of Mailing: Date of Deposit: September 15, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine E. Fort
Printed name of person mailing correspondence

Christine E. Fort
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gilles et al.	Confirmation No.:	4465
Serial No.:	10/523,444	Art Unit:	1644
Filed:	January 31, 2005	Examiner:	M. E. Szperka
Customer No.:	21559		
Title:	ANTI-IDIOTYPIC ANTIBODIES AGAINST FACTOR VIII INHIBITOR AND USES THEREOF		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Copies of an International Search Report and International Preliminary Examination Reports are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on January 31, 2005, and that they have not yet received an initialed copy of the Form PTO-1449. Applicants thus request an initialed copy of the Form PTO-1449.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 15-Sep-2006



James D. DeCamp
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/059001
	Serial No.	10/523,444
	Applicant	Gilles et al.
	Filing Date	Jan. 31, 2005
	Group	1641
	IDS Filed	September 15, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/58680	11/18/99	WIPO			
	WO 01/04269	01/18/01	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Algiman et al., "Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals," <i>Proceedings of the National Academy of Sciences USA</i> 89: 3795-3799 (1992).					
	Gilles et al., "Antibodies to idiotypes of human monoclonal anti-factor VIII (FVIII) antibodies neutralise their inhibitory activity," <i>Blood</i> , 94(10 Suppl. 1 Part 1) 460a, Abstract# 2048 (1999-11-15).					
	Gilles et al., "Anti-factor VIII Antibodies of Hemophiliac Patients are Frequently Directed Towards Nonfunctional Determinants and Do Not Exhibit Isotypic Restriction," <i>Blood</i> 82(8): 2452-2461 (1993).					
	Gilles et al., "Healthy Subjects Produce both Anti-Factor VIII and Specific Anti-Idiotypic Antibodies," <i>Journal of Clinical Investigation</i> 94(4): 1496-1505 (1994).					
	Gilles et al., "Neutralizing Antiidiotypic Antibodies to Factor VIII Inhibitors after Desensitization in Patients with Hemophilia A," <i>Journal of Clinical Investigation</i> 97(6): 1382-1388 (1996).					
	Jacquemin et al., "A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor," <i>Blood</i> 95(1): 156-163 (2000).					
	Jacquemin et al., "Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived From a Hemophilia A Patient With Inhibitor" <i>Blood</i> 92(2): 496-506 (1998).					
	Kaufman et al., "Synthesis, Processing, and Secretion of Recombinant Human Factor VIII Expressed in Mammalian Cells," <i>The Journal of Biological Chemistry</i> 263(13): 6352-6362 (1988).					
	Lenting et al., "The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-related Protein," <i>The Journal of Biological Chemistry</i> 274(34): 23734-23739 (1999).					
	Lubahn et al., "Characterization of a monoclonal anti-idiotypic antibody to human anti-factor VIII antibodies,"					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/059001
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>		Serial No.	10/523,444
		Applicant	Gilles et al.
		Filing Date	Jan. 31, 2005
		Group	1641
		IDS Filed	September 15, 2006
(37 C.F.R. § 1.98(b))			

	<i>Proceedings of the National Academy of Sciences USA</i> 87: 8232-8236 (1990).
	Manivel et al., "Maturation of an Antibody Response Is Governed by Modulations in Flexibility of the Antigen-Combining Site," <i>Immunity</i> 13: 611-620 (2000).
	Pratt et al., "Structure of the C2 domain of human factor VIII at 1.5 Å resolution," <i>Nature</i> 402: 439-442 (1999).
	Saenko et al., "Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism," <i>The Journal of Biological Chemistry</i> 274(53): 37685-37692 (1999).
	Saint-Remy et al., "Anti-Idiotypic antibodies: From Regulation to Therapy of Factor VIII Inhibitors," <i>Vox Sanguinis</i> , S. Karger AG, Basel, CH, 77(Suppl. 1): 21-24 (1999).
	Singh et al., "Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model," <i>Blood</i> 99(9): 3235-3240 (2002).
	Spiegel Jr. et al., "Structure of a factor VIII C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII," <i>Blood</i> 98(1): 13-19 (2001).
	Van den Brink et al., "Two classes of germline genes both derived from the V _H 1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII," <i>Blood</i> 99(8): 2828-2834 (2002).
	Wilbur et al., "Rapid similarity searches of nucleic acid and protein data banks," <i>Proceedings of the National Academy of Sciences USA</i> 80: 726-730 (1983).
	International Search Report issued in PCT/EP03/08365 (dated December 4, 2003)
	International Preliminary Examination Report issued in PCT/EP03/08365 (dated August 17, 2004)
	International Preliminary Examination Report issued in PCT/EP03/08365 (dated September 21, 2004)
	Genebank accession number: AAW27416 corresponding to the international application WO9710354 (Kyowa Hakko Kogyo KK). 20-03-1997
	Genebank accession number: AAR52526 corresponding to the European application EP592106 (Immunogen Inc.) 13-04-1994
	Genebank accession number: AX417628 corresponding to the international application number WO231510 (PEPSCAN SYSTEMS BV) (NL) 18-06-2002.
	Genebank accession number: AR144014 corresponding to the U.S. patent US6210671-A/3 (Protein Design Labs, Inc.) 03-04-2001
	Genebank accession number: AAT38510 corresponding to the international application WO9632495-A/1 (LG Chem Ltd.) 06-04-1996

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	